Introduction
============

Glucocorticoids (GC) are a naturally occurring catabolic steroid, produced by the hypothalamic--pituitary--adrenal (HPA) axis and regulated by neuroendocrine and immune responses ([@bib1], [@bib2]). Synthetic forms of GC, such as prednisolone, are used primarily for anti-inflammatory purposes in the treatment of numerous acute and chronic illnesses and diseases ([@bib3], [@bib4], [@bib5]). As much as 17% of the population are prescribed GC on an annual basis, indicating the substantial prevalence of GC administration ([@bib6]).

GC are often used by athletes for their proposed ergogenic effects, which has resulted in the World Anti-Doping Agency banning their use during competition. Several recent reviews suggest that short-term (\>2 weeks) GC treatment likely has an ergogenic effect on exercise capacity and performance ([@bib7], [@bib8]). However, the effects of acute (single dose) GC administration are less clear, largely due to limited research. As such, it is important to determine the biological effects of acute GC treatment, not only for the potential effects on performance but also for the health implications associated with GC treatment.

GC administration at supraphysiological doses can result in severe systemic side effects. In severe cases of prolonged GC treatment, this can result in iatrogenic Cushing's syndrome with skin thinning and bruising, reduced bone density, accumulation of central adiposity, skeletal muscle wasting and hyperglycaemia ([@bib9]). The withdrawal of exogenous GC or minimisation of dose and duration of therapy are recommended to minimise GC-induced side effects ([@bib10]). However, this is not always possible and as such additional pharmaceutical drugs are often prescribed to treat GC-related symptoms, which may lead to the development of further unwanted side effects ([@bib10]). Emerging research from animal studies has demonstrated the potential for exercise to be a viable alternative for managing certain GC-induced side effects, including skeletal muscle atrophy and insulin resistance ([@bib11], [@bib12], [@bib13]). Yet, there is little evidence in humans regarding the potential benefits of exercise to treat and manage the cardiometabolic side effects of GC treatment.

In men, chronic or long-term GC treatment is associated with a reduction in circulating testosterone concentrations attributed to the inhibition of the hypothalamic--pituitary--testicular (HPT) axis ([@bib14]). Exercise is not thought to interfere with the diurnal rhythm of testosterone production ([@bib15]), and there may be a short-term effect of exercise training to reduce metabolic clearance of testosterone ([@bib16]). However, how acute administration of GC may modulate sex hormone responses to exercise in men is unclear.

Therefore, the primary aims of this study were (A) to determine whether a single dose of prednisolone can influence exercise performance during high-intensity interval cycling and (B) to investigate the effects of acute prednisolone administration on metabolic, haematological and hormonal outcomes and determine the response to high-intensity exercise.

Methods
=======

This study is part of a larger study and as such a detailed description of the methodology is provided elsewhere ([@bib17], [@bib18]). In short, nine healthy, recreationally active males (age: 27.8 ± 1.7 years; BMI: 24.4 ± 0.8; fasting blood glucose: 4.7 ± 0.2 mmol/L, Mean ± [s.e.m.]{.smallcaps}) participated in this double-blind, randomised controlled, cross-over study. The participants orally ingested either prednisolone (20 mg) or placebo (Avicel), 12 h prior to undergoing an acute exercise session. The second session (either prednisolone or placebo) was completed after a washout period of at least 1 week. The high-intensity interval exercise (HIIE) consisted of 4 × 4 min cycling bouts at 90--95% of peak heart rate, interspersed with 2-min recovery periods at 50--60% of peak heart rate. We, and others, have previously reported that this type of exercise elicits favourable improvements in glycaemic control, compared to moderate-intensity exercise ([@bib19], [@bib20]). The workload for the second session was continuously modified throughout the exercise to elicit the same heart rate achieved during the first session. Informed consent was obtained from each participant and the study was approved by the Victoria University Human Research Ethics Committee.

Blood samples were taken prior to exercise, immediately after exercise, and 30 min, 1 h, 2 h and 3 h post exercise. Blood glucose and lactate concentrations were analysed using YSI 2300 STAT Plus (Glucose & Lactate Analyser, Australia). White blood cell (WBC) counts, red blood cell (RBC) counts, haemoglobin and haematocrit concentrations were analysed with a Sysmex KX -- 21N (Kobe, Japan). Serum testosterone and dihydrotestosterone (DHT) were measured by liquid chromatography mass-spectrometry using a Xevo TQ-S (Waters Corporation, Milford, MA, USA) with prior liquid-liquid extraction using methyl tert-butyl ether. The lowest limit of detection of testosterone and DHT is 0.08 nmol/L. Serum oestradiol (E2) was analysed by liquid chromatography mass spectrophotometry following derivatisation with Dansyl Chloride. The lowest limit of detection is 5 pmol/L. The between-run imprecision for LCMS analysis of testosterone, DHT and E2 over the analytical range is 5--10%. Serum sex hormone-binding globulin (SHBG) was analysed on an Immulite 2000 (Siemens Healthcare Diagnostics Inc.) and luteinizing hormone (LH) on an Architect Analyser (Abbott Diagnostics).

Statistical analysis
--------------------

Data were checked for normality and analysed using Predictive Analytics Software (PASW, SPSS Inc.). Comparison of means was examined using a two-way (Treatment × Time) repeated-measures ANOVA. For all significant interaction and main effects, *a priori* comparisons of means (baseline vs all post-exercise time-points; placebo vs glucocorticoid for all time-points) were conducted using Fisher's least significant difference test (*P* \< 0.05). All data are reported as mean ± standard error of mean ([s.e.m.]{.smallcaps}) and all statistical analysis were conducted at the 95% level of significance (*P* ≤ 0.05). Trends were reported when *P* values were greater than 0.05 and less than 0.1. Effect sizes (ESs) were calculated using Cohen's d equation.

Results
=======

Exercise performance
--------------------

Prednisolone did not significantly affect the work performed in the first bout of HIIE. In contrast, prednisolone significantly decreased the work performed in the final three HIIE bouts, the difference became greater with each subsequent set (ES: 0.22--0.41, [Fig. 1](#fig1){ref-type="fig"}). Overall, the total work performed during the exercise session was significantly lower with prednisolone compared to placebo (prednisolone: 206 kj; placebo: 217 kj, *P* \< 0.05). As expected, HR was not significantly different between each set, with and without prednisolone, as each set was matched according to HR (all *P* \> 0.05, ES: 0.03--0.14). However, the mean difference for the entire session was slightly higher (1.5 bpm, *P* \< 0.05, ES: 0.1) following prednisolone ([Fig. 1](#fig1){ref-type="fig"}).Figure 1Mean work output (Watts) (solid bars) and heart rate (HR) (striped bars) during the high-intensity cycling sets. Δ expressed as a percentage difference between treatments. **\*\****P* \< 0.01, **\****P* \< 0.05 prednisolone significantly different from placebo.

Blood glucose
-------------

Prednisolone ingestion caused a significant increase in blood glucose concentration at baseline, immediately following exercise and 30 min, 1 and 2 h after exercise, compared to placebo (ES: 0.55--2.19, [Fig. 2A](#fig2){ref-type="fig"}). Blood glucose concentration in the placebo trial was not significantly altered from baseline throughout the session. Three hours following exercise, blood glucose levels in the prednisolone session were equivalent to the glucose concentration in the placebo session (*P* \> 0.05).Figure 2(A) Blood glucose, (B) blood lactate responses (means ± [s.e.m.]{.smallcaps}) 12 h post capsule ingestion (baseline), immediately post exercise (Post-ex) and throughout recovery: 30 min, 1 h, 2 h and 3 h with prednisolone and placebo treatment. **\****P* \< 0.05, **\*\****P* \< 0.01, **\*\*\****P* \< 0.001 between prednisolone and placebo treatment. (a) Different from baseline values with prednisolone ingestion (*P* \< 0.05). (b) Different from baseline values with placebo treatment (*P* \< 0.05).

Blood lactate
-------------

The acute administration of prednisolone did not alter baseline blood lactate concentrations. The HIIE caused an increase blood lactate concentration with both treatments; however, the increase in lactate was reduced by 14% with prednisolone compared to the placebo (*P* \< 0.05, ES: 0.55) ([Fig. 2B](#fig2){ref-type="fig"}). Blood lactate returned to baseline levels after 1 h of recovery in the prednisolone session, but remained elevated above baseline for up to 3 h post-exercise in the placebo session ([Fig. 2B](#fig2){ref-type="fig"}).

Haematology
-----------

Due to machine technical difficulties which resulted in missing data, results for haematological variables are reported for seven participants only.

In comparison to baseline, whole blood WBC concentration was significantly increased immediately following exercise, 2 and 3 h after exercise, for both treatments ([Fig. 3A](#fig3){ref-type="fig"}). Compared to placebo, prednisolone caused a significant elevation in whole blood WBC counts at all time-points (*P* \< 0.01, ES: 1.18--2.01).Figure 3(A) White blood cell (WBC) count, (B) red blood cell (RBC) count, (C) haemoglobin (HGB), (D) haematocrit (HCT) responses (mean ± [s.e.m.]{.smallcaps}) 12 h post capsule ingestion (Baseline), immediately post exercise (Post-ex) and throughout recovery: 1 h, 2 h and 3 h with prednisolone and placebo treatment. **\*\****P* \< 0.01 between prednisolone and placebo. ^\#^*P* \< 0.05 difference from baseline values with treatments combined.

The HIIE caused a significant increase in whole blood RBC, haemoglobin and haematocrit immediately post exercise for both treatments (*P* \< 0.05, ES: 1.2--2.23) ([Fig. 3B](#fig3){ref-type="fig"}, [C](#fig3){ref-type="fig"} and [D](#fig3){ref-type="fig"}). With both treatments combined whole blood RBC count decreased below baseline levels at 1 h post exercise (*P* \< 0.05). Similarly, haemoglobin and haematocrit concentrations were decreased below baseline levels for up to 1 h after exercise (*P* \< 0.05), returning to baseline levels 2 and 3 h into recovery. Prednisolone had no significant effect on whole blood RBC count, haemoglobin or haematocrit compared to placebo (*P* \< 0.05, ES: 0--0.32).

Sex hormones
------------

Serum concentrations of testosterone, DHT and SHBG increased immediately after exercise with both placebo and prednisolone treatments combined ([Fig. 4A](#fig4){ref-type="fig"}, [B](#fig4){ref-type="fig"} and [E](#fig4){ref-type="fig"}, *P* \< 0.05). DHT and SHBG concentrations decreased below baseline levels 1 h following exercise, before returning to pre-exercise levels 3 h post exercise ([Fig. 4B](#fig4){ref-type="fig"} and [E](#fig4){ref-type="fig"}). Similarly, testosterone decreased below baseline levels 1 h into recovery and remained reduced at 3 h post exercise ([Fig. 4A](#fig4){ref-type="fig"}). E2 was significantly elevated above baseline concentrations 3 h after exercise, irrespective of treatment ([Fig. 4C](#fig4){ref-type="fig"}, ES: 0.46--0.82).Figure 4(A) Testosterone (T), (B) dihydrotestosterone (DHT), (C) oestradiol (E2), (D) luteinizing hormone (LH), (E) sex hormone-binding globulin (SHBG) responses (mean ± [s.e.m.]{.smallcaps}) 12 h post capsule ingestion (Baseline), immediately post exercise (Post-ex) and throughout recovery: 1 h and 3 h with prednisolone and placebo treatment. ^\#^*P* \< 0.05 difference from baseline values with treatments combined.

A trend was observed for higher LH at all time-points with prednisolone; however, the effect was not significant (*P* = 0.087, ES: 0.17--1.24) ([Fig. 4D](#fig4){ref-type="fig"}). A significant treatment effect was observed in the ratio of testosterone/LH, with prednisolone causing a reduction in the ratio of testosterone/LH at all time-points in comparison to placebo ([Fig. 5A](#fig5){ref-type="fig"}, *P* \< 0.01, ES: 0.56--1.3). Prednisolone did not significantly alter the testosterone/E2 ratio ([Fig. 5B](#fig5){ref-type="fig"}).Figure 5(A) Testosterone (T)/luteinizing hormone (LH) ratio, (B) testosterone (T)/oestradiol (E2) ratio (mean ± [s.e.m.]{.smallcaps}) 12 h post capsule ingestion (Baseline), immediately post exercise (Post-ex.) and throughout recovery: 1 h and 3 h with prednisolone and placebo ingestion. **\*\****P* \< 0.01 between prednisolone and placebo.

Discussion
==========

The major findings of this study are (A) a single dose of prednisolone decreases work capacity during HIIE at ∼95% of peak HR in healthy young men; (B) prednisolone significantly elevates fasting blood glucose concentrations which is restored to baseline 3 h after HIIE; (C) exercise acutely affects WBC counts and sex hormones which persists up to 3 h after exercise, while prednisolone reduces the ratio of testosterone/LH.

There is a lack of evidence regarding the effect of acute (single dose) GC treatment during HIIE, despite short-term GC treatment indicating an ergogenic effect ([@bib7], [@bib8]). We report a significant reduction in the work completed, at the same relative intensity during HIIE, with prior prednisolone ingestion. This finding corresponds with a previous study which reported that acute prednisolone ingestion (20 mg) increased VO~2~ during steady state cycling at 60% of VO~2max~, indicating an increased energy demand during submaximal exercise, which may indicate reduced exercise efficiency ([@bib21]). In contrast, HIIE following an acute 4 mg dose of dexamethasone appears to have no effect on VO~2~ or HR ([@bib22]). Similarly, single-dose prednisolone (20 mg) has no effect on time to exhaustion at intensities between 70 and 85% of VO~2max~ ([@bib23], [@bib24]). Together, the current evidence indicates that acute prednisolone reduces exercise capacity, especially at higher intensities, when the metabolic demand is high. The mechanisms by which GC reduces exercise capacity are not clear, but may be related to the acute effect of GC on skeletal muscle protein signalling including aberrant anabolic and insulin signalling proteins ([@bib18]), and/or impaired skeletal muscle microvascular blood flow ([@bib25]), both known mediators of exercise capacity. The discrepancy between our findings and others that have reported improved exercise performance after short-term GC is equally unclear ([@bib26], [@bib27], [@bib28]). It could be speculated that a single dose of GC elicits a perturbation in whole-body homeostasis, including impaired glycaemic control as indicated by elevated fasting glucose and insulin. In contrast, longer duration GC treatment (albeit still short term) may promote compensatory mechanisms that are able to control this initial homeostatic insult, which may reflect why some studies have reported normal fasting glucose and insulin after short-term GC treatment ([@bib28], [@bib29]). Further research is warranted to explore the effect of acute prednisolone on exercise capacity and performance during other exercises and sports and to investigate the potential mechanisms.

Chronic GC treatment is known to induce side effects including hyperglycaemia and the development of diabetes ([@bib30], [@bib31]). However, the effects of a single-dose GC on fasting and post-exercise blood glucose levels in healthy individuals are not clear, and some reported that prednisolone (20 mg) causes an increase in blood glucose concentrations at baseline ([@bib23], [@bib24], [@bib32]), while others reported that it has no effect on blood glucose ([@bib21], [@bib22], [@bib33]). The results from the current study confirms that a single dose of prednisolone significantly increases blood glucose levels.

Exercise is known to improve insulin sensitivity and glucose regulation in healthy individuals and people who live with chronic conditions, including insulin resistance and type 2 diabetes ([@bib34], [@bib35]). We report that prednisolone-induced hyperglycaemia was restored to baseline levels 3 h after a single session of HIIE. It is possible that the restoration of glucose levels after exercise may, in part, be due to the degradation of the biological activity of a single dose of prednisolone over the course of time. However, previous studies have also reported restoration of glucose levels when cycling exercise (80--85% of VO~2max~) is performed as little as 2--3 h after prednisolone (20 mg) ingestion ([@bib23]). These findings highlight the important role exercise can play in improving glycaemic control during GC therapy. The effect of exercise on blood glucose may depend on the dosage of GC administered. For instance, both 1 and 4 mg doses of dexamethasone increase blood glucose levels at baseline, however, normalisation of blood glucose with exercise at 90% of VO~2max~ occurs with only the 1 mg dose ([@bib32]). It is also possible that the normalisation of glucose levels is intensity dependant. Exercise at 70--75% of VO~2max~ has previously been reported to have limited effect on blood glucose response following prednisolone treatment (20 mg) ([@bib24]). The current findings provide new evidence that acute HIIE may help to minimise the elevation in blood glucose concentration that occurs following GC treatment. However, further research is required to confirm these findings with respect to timing of exercise following ingestion of GC and identifying the mechanisms involved (i.e. improved glucose uptake by skeletal muscle, a reduction in hepatic glucose output or both).

To determine the influence of prednisolone on other exercise-mediated metabolic responses, we measured blood lactate and changes in blood haematology. Blood lactate significantly increased from resting levels in response to HIIE with both treatments. However, the lactate response was supressed in the prednisolone trial compared to the placebo, possibly a reflection of the significant reduction in work performed during the exercise session. This finding is in contrast to previous studies which reported that blood lactate was not altered with prednisolone ([@bib21], [@bib23], [@bib24]) and dexamethasone treatment ([@bib22], [@bib32]). Furthermore, none of these studies reported a change in exercise performance, which supports the hypothesis that lactate was likely reduced in the current study due to the reduction in work completed. It is also possible that the use of a long duration, HIIE protocol in the current study may, in part, explain the discrepancy in findings, given that lactate metabolism is crucial in sustaining intense exercise ([@bib36]).

GC therapy is used as an immunosuppressive agent to treat autoimmune diseases. However, little research has been conducted to explore the immune response following GC administration and exercise. We report that acute prednisolone ingestion causes an elevation in total WBC count at baseline (12 h after ingestion), and throughout the 3-h recovery period following HIIE. Similarly, the short-term inhalation of fluticasone results in an increase in total WBC and neutrophils at baseline, with a further increase following high-intensity exercise ([@bib37]). However, another study reported that lymphocyte concentration was reduced in a time-dependent manner following prednisone ingestion ([@bib38]), suggesting that specific WBC subtypes may respond differently to exercise and GC ingestion, warranting further investigation.

Changes in RBC count, haemoglobin and haematocrit are reported to influence exercise performance predominantly through the contribution of oxygen to working muscles ([@bib39]). Therefore, we investigated whether the decreased exercise capacity with prednisolone ingestion would coincide with changes in these variables. Although the RBC count, haemoglobin and haematocrit were altered following HIIE, there was no treatment effect of prednisolone suggesting alternative pathways are likely for the impairment of exercise capacity.

Given the potential of androgen-glucocorticoid interactions and the role of hormonal regulation for exercise performance and adaptation ([@bib40], [@bib41]), we explored the effects of single-dose GC treatment on circulating sex hormone concentrations before and after a single session of HIIE. We report that HIIE increased circulating androgens, namely testosterone and DHT, as well as SHBG concentrations. While DHT and SHBG returned to baseline levels during recovery, testosterone concentrations remain below baseline, suggesting a biphasic response of testosterone to HIIE. E2 concentrations were stable during exercise and increased during recovery. The ratio of testosterone/LH is reduced in men after taking prednisolone consistent with evidence of testicular, or more specifically Leydig cell, dysfunction ([@bib42], [@bib43]). Prednisolone reduced the ratio of testosterone/LH across all time-points consistent with an effect to impair testicular Leydig cell function superimposed on the effect of exercise. This occurred in the absence of any evidence of altered aromatase activity as the ratio of testosterone/E2 was unchanged ([@bib44]). This acute effect of prednisolone on Leydig cell function is noteworthy. Chronic GC therapy has been associated with lower circulating testosterone concentrations without elevation of LH, attributed to suppression of central components of the HPT axis ([@bib14], [@bib45], [@bib46]). Our findings suggest that impairment of Leydig cell function may also play a role in the action of GC on the HPT axis. Further studies are warranted to ascertain the effects of chronic GC administration on Leydig cell function, and whether GC use impacts on multiple levels of the HPT axis.

Testosterone treatment in younger and older men has an anabolic effect including increased muscle strength and performance ([@bib40], [@bib41]). The acute effect of exercise to increase testosterone, DHT and SHBG could reflect an element of haemoconcentration following exercise. The reduction in testosterone post exercise but not DHT or SHBG would be consistent with downregulation of the HPT axis in the setting of fatigue. Further studies would be needed to establish whether chronic GC administration and more sustained periods of exercise might jointly impact on the function of the HPT axis to the detriment of exercise capacity.

This study has several potential limitations; first, there is a relatively small sample size. This study was conducted as part of a larger, invasive study, and as such, recruitment was difficult ([@bib18]). This study was adequately powered to compare changes in blood glucose from baseline to 3 h post exercise, between placebo and prednisolone, *P* \< 0.05, effect size of 2.65; *n* = 9; power of 99%, which was the main outcome of the project. We also identified a significant difference in watts between placebo and prednisolone; however, a *post hoc* power calculation (G\*Power 3.1.9.2; two-tailed dependent *t*-test, alpha = 0.05) demonstrated that it was underpowered (effect size of 0.41; *n* = 9; power of 23%). As such, future studies should include a larger sample size to account for an adequate power. Second, due to the metabolic differences between males and females, only males were tested in this study. As such, and acknowledging the differences in reproductive physiology between males and females, the results may not be applicable to females. It will be important to conduct further research in females to identify whether GC treatment has a different effect. Furthermore, the participants in this study were young and healthy, and as such these findings are delimited to this specific population with further research require to explore the effects of GC ingestion and exercise in other populations. Finally, the participants were given access to water *ad libitum*, it is possible that some of the changes in the haematological outcomes may be due to alterations in plasma volume.

In conclusion, a single dose of prednisolone decreases work performed during high-intensity interval cycling that suggests that acute GC administration does not act as an ergogenic aid, and in fact may reduce exercise performance. Prednisolone also increases basal blood glucose concentrations, impairs Leydig cell function and increases WBC count. Importantly, acute HIIE restores euglycaemia which may indicate HIIE as a potential treatment strategy for counteracting GC-induced hyperglycaemia. Whether HIIE training can reduce the serious metabolic side effects of chronic GC administration warrants further investigation.
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